# The DARE Warfarin CER Study

> **NCT03271450** · — · UNKNOWN · sponsor: **Brigham and Women's Hospital** · enrollment: 416000 (estimated)

## Conditions studied

- Deep Venous Thrombosis
- Pulmonary Embolism

## Interventions

- **DRUG:** Dabigatran: extended treatment (e.g at least 90 days)
- **DRUG:** Dabigatran: extended treatment (e.g at least 180 days)
- **DRUG:** Dabigatran: extended treatment (e.g at least 270 days)
- **DRUG:** Apixaban: extended treatment (e.g at least 90 days)
- **DRUG:** Apixaban: extended treatment (e.g at least 180 days)
- **DRUG:** Apixaban: extended treatment (e.g at least 270 days)
- **DRUG:** Rivaroxaban: extended treatment (e.g at least 90 days)
- **DRUG:** Rivaroxaban: extended treatment (e.g at least 180 days)
- **DRUG:** Rivaroxaban: extended treatment (e.g at least 270 days)
- **DRUG:** Edoxaban: extended treatment (e.g at least 90 days)
- **DRUG:** Edoxaban: extended treatment (e.g at least 180 days)
- **DRUG:** Edoxaban: extended treatment (e.g at least 270 days)
- **DRUG:** Warfarin: extended treatment (e.g at least 90 days)
- **DRUG:** Warfarin: extended treatment (e.g at least 180 days)
- **DRUG:** Warfarin: extended treatment (e.g at least 270 days)

## Key facts

- **NCT ID:** NCT03271450
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-10-30
- **Target enrollment:** 416000 (ESTIMATED)
- **Last updated:** 2021-06-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03271450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03271450, "The DARE Warfarin CER Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03271450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*